BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, P38, and HIV protease

被引:125
作者
Pierce, AC [1 ]
Rao, G [1 ]
Bemis, GW [1 ]
机构
[1] Vertex Pharmaceut, Cambridge, MA 02139 USA
关键词
D O I
10.1021/jm030543u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this work we describe BREED, a method for the generation of novel inhibitors from structures of known ligands bound to a common target. The method is essentially an automation of the common medicinal chemistry practice of joining fragments of two known ligands to generate a new inhibitor. The ligand-bound target structures are overlaid, all overlapping bonds in all pairs of ligands are found, and the fragments on each side of each matching bond are swapped to generate the new molecules. Since the method is automated, it can be applied recursively to generate all possible combinations of known ligands. In an application of this method to HIV protease inhibitors and protein kinase inhibitors, hundreds of new molecular structures were generated. These included known inhibitor scaffolds not included in the initial set, entirely novel scaffolds, and novel substituents on known scaffolds. The method is fast, and since all of the ligand functional groups are known to bind the target in the precise position and orientation present in the novel ligand, the success rate of this method should be superior to more traditional de novo design techniques. In an era of increasingly high-throughput structural biology, such methods for high-throughput utilization of structural information will become increasingly valuable.
引用
收藏
页码:2768 / 2775
页数:8
相关论文
共 36 条
[1]  
ARMISTEAD DM, 2001, Patent No. 0160816
[2]  
ASTRAZENECA AB, 2001, Patent No. 0164655
[3]  
ASTRAZENECA AB, 2001, Patent No. 0164654
[4]   X-RAY CRYSTAL-STRUCTURE OF THE HIV PROTEASE COMPLEX WITH L-700,417, AN INHIBITOR WITH PSEUDO C2 SYMMETRY [J].
BONE, R ;
VACCA, JP ;
ANDERSON, PS ;
HOLLOWAY, MK .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1991, 113 (24) :9382-9384
[5]  
CHEN ZG, 1994, J BIOL CHEM, V269, P26344
[6]   The cyclin-dependent kinases cdk2 and cdk5 act by a random, anticooperative kinetic mechanism [J].
Clare, PM ;
Poorman, RA ;
Kelley, LC ;
Watenpaugh, KD ;
Bannow, CA ;
Leach, KL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (51) :48292-48299
[7]  
CUMMING JG, 2001, Patent No. 0127089
[8]   DESCRIPTION OF SEVERAL CHEMICAL-STRUCTURE FILE FORMATS USED BY COMPUTER-PROGRAMS DEVELOPED AT MOLECULAR DESIGN LIMITED [J].
DALBY, A ;
NOURSE, JG ;
HOUNSHELL, WD ;
GUSHURST, AKI ;
GRIER, DL ;
LELAND, BA ;
LAUFER, J .
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES, 1992, 32 (03) :244-255
[9]   Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates.: A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor [J].
Dohnálek, J ;
Hasek, J ;
Dusková, J ;
Petroková, H ;
Hradilek, M ;
Soucek, M ;
Konvalinka, J ;
Brynda, J ;
Sedlácek, J ;
Fábry, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (07) :1432-1438
[10]   Prediction of intestinal permeability [J].
Egan, WJ ;
Lauri, G .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (03) :273-289